New hope for rare artery disease? upadacitinib shows promise in small trial
NCT ID NCT07500467
First seen Apr 13, 2026 · Last updated Jun 23, 2026 · Updated 14 times
Summary
This study tested the drug upadacitinib in 12 people with Takayasu arteritis, a rare autoimmune disease that inflames the body's largest artery. All participants had active disease that did not improve with standard treatments. The goal was to see if upadacitinib could help achieve remission within 24 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TAKAYASU ARTERITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Department of Rheumatology and Immunology, Peking University People's Hospital
Beijing, Beijing Municipality, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
upadacitinib
What this could lead to
If it works, this could offer a new oral treatment option for people with Takayasu arteritis who haven't responded to standard therapies.
What could go wrong
This is a very small, early-phase study with only 12 participants, so results may not apply broadly. Upadacitinib also carries risks like infection and blood clots.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.